33 results about "Glycoalkaloid" patented technology

The present invention relates to methods and compositions for reducing the appearance of dynamic facial wrinkles by administering oral and / or topical compositions comprising therapeutically-effective amounts of extracts of one or more relaxing herbal agents (“RHAs”) alone or in combination with one or more extracts of an edible solanaceous glycoalkaloid-containing plant (“ESGP”) or an edible glycoalkaloid-containing fungus (“EGF”) selected from plant species in the genus Solanum and mushrooms. RHAs are selected from the group consisting of extracts of Q. amara, E. angustifolia, P. oleracea, M. dubia, P. orientalis and A. muscaria and plant species from the genus Valeriana, Passiflora, Verbascum, Scutellaria, Cypripedium, Magnolia, Atriplex and Symphytum. Additionally, the methods of the present invention may comprise exfoliating the skin, preferably with at least one acid protease enzyme.

The present invention relates to key genes in the biosynthesis of steroidal alkaloids and saponins, including regulatory genes and enzyme-encoding genes, and to use thereof for altering the content of steroidal (glyco)alkaloids or phytosterols in plants. The present invention provides genetically modified plants or gene edited plants with altered content of steroidal (glyco)alkaloids, particularly to Solanaceous crop plants with reduced content of antinutritional steroidal glycoalkaloids and to the increase in phytosterols, including cholesterol or cholestanol in these plants. The present invention also provides methods of altering gene expression.

The invention discloses a medicine for treating lung cancer pleural effusion. The medicine is prepared from the following raw materials: kansui root, euphorbia pekinensis, lilac daphne flower bud, semen brassicae, semen lepidii, cortex mori radicis, pinellia ternate, Chinese-date, grifola, poria cocos, cassia twig, plantain herb, bighead atractylodes rhizome, oldenlandia diffusa, Chinese lobelia, semen coicis, trichosanthes peel, root of red-rooted salvia, roasted draba nemorosa, verbena, perillaseed, rhizoma pinellinae praeparata, tribulus terrestris, herba lycopi, bunge pricklyash seed, reddish orange, leech, allium macrostemon, almond, liquorice, root of straight ladybell, radix ophiopogonis, radix polygonati officinalis, radices trichosanthis, cortex lycii radicis, woodlouse, bombyx batryticatus, earthworm, cricket, mole cricket, glycoalkaloids, bufo gargarizans, salvia chinensis, radix sophorae flavescentis, rhizoma pleionis, burdock, subprostrate sophora root, tripterygium glycosides, turtle shell, elecampane, frankincense, myrrh, bighead atractylodes rhizome, corydalis tuber and radix paeoniae alba. The medicine has obvious effects of discharging water and removing stasis on a patient with lung cancer pleural effusion, simultaneously can be used for tonifying qi, relieving cough and reducing sputum, nourishing the blood, promoting blood circulation and relieving pain, and resolving hard lumps and eliminating mass, so that the living quality of the patient is improved, the life is prolonged, and the effective rate can reach 90%.

The present invention relates to methods and compositions for reducing the appearance of dynamic facial wrinkles by administering oral and / or topical compositions comprising therapeutically-effective amounts of extracts of one or more relaxing herbal agents (“RHAs”) alone or in combination with one or more extracts of an edible solanaceous glycoalkaloid-containing plant (“ESGP”) or an edible glycoalkaloid-containing fungus (“EGF”) selected from plant species in the genus Solanum and mushrooms. RHAs are selected from the group consisting of extracts of Q. amara, E. angustifolia, P. oleracea, M. dubia, P. orientalis and A. muscaria and plant species from the genusValeriana, Passiflora, Verbascum, Scutellaria, Cypripedium, Magnolia, Atriplex and Symphytum. Additionally, the methods of the present invention may comprise exfoliating the skin, preferably with at least one acid protease enzyme.

The present invention in its broadest aspect relates to a method for reducing glycoalkaloid content and turbidity of an aqueous phase comprising compounds selected from two or more of PA, PI, PPO, LipO, pectin, lipid, glycoalkaloid and phenolic compounds of which at least one compound is selected from PA, PI, LipO and PPO; a) providing an aqueous phase comprising compounds selected from two or more of PA, PI, PPO, LipO, pectin, lipid, glycoalkaloid and phenolic compounds of which at least one compound is selected from PA, PI, LipO and PPO; and b) performing one or more steps to reduce the concentration of solanine in the dry matter of the aqueous phase with at least 15 percent, such as at least 20% such as at least 25% and to achieve an optical density at 620 nm of the remaining aqueous phase of less than 0.7; such as less than 0.5; such as less than 0.3; such as less than 0.2 such as less than 0.1 and thereby obtaining an aqueous phase having reduced glycoalkaloid content and turbidity compared to an untreated aqueous phase.

A method for the preparation of a food grade coagulated potato protein concentrate is disclosed, wherein it comprises the steps of a) separating fibers and starch from a potato pulp, wherein a potato fruit juice containing potato protein is obtained, b) coagulating the potato protein in the potato fruit juice by adjusting the pH to an acidic value and by heating, wherein a coagulated potato protein slurry containing particles of coagulated potato protein is obtained, c) reducing the total glycoalkaloid content in the coagulated potato protein slurry to less than 150 mg / kg protein concentrate, and d) actively reducing the particle size of the of potato protein particles by physical means in such a way that a coagulated potato protein concentrate is obtained in which 90% of said particles have a particle size of less than 55 μm, as well as a food grade coagulated potato protein concentrate produced with said method, use of the food grade coagulated potato protein concentrate in a food product, and a food product for human use comprising said food grade coagulated potato protein product.

A composition of chemically purified soluble mannans from legumes' seeds (e.g. Ceratonia siliqua, Caesalpinia spinosa Trigonelle foenum-graecum, and Cyamopsis tetragonolobus) and their use in the assembly of palatable dietary supplements is disclosed herein. The fractionation process provides high-quality physiologically soluble, chemically modified and purified homogeneous size polysaccharide fibers, devoid of natural impurities, for example proteins, alkaloids, glycoalkaloids, and / or environmental impurities including heavy metals, agricultural residues and microbial toxins. This process provides hypoallergenic dietary fibers devoid of any potential allergens, cytotoxins, and gastrointestinal toxins. A sequential process for assembly of the soluble fibers with plurality of molecular weights to create a time controlled dissolution of the functional high and low molecular weight fibers for improving solubility and palatability with improved dietary performance in the oral and gastro-intestinal system is also disclosed herein.

A composition of chemically purified soluble mannans from legumes' seeds (e.g. Ceratonia siliqua, Caesalpinia spinosa Trigonelle foenum-graecum, and Cyamopsis tetragonolobus) and their use in the assembly of palatable dietary supplements is disclosed herein. The fractionation process provides high-quality physiologically soluble, chemically modified and purified homogeneous size polysaccharide fibers, devoid of natural impurities, for example proteins, alkaloids, glycoalkaloids, and / or environmental impurities including heavy metals, agricultural residues and microbial toxins. This process provides hypoallergenic dietary fibers devoid of any potential allergens, cytotoxins, and gastrointestinal toxins. A sequential process for assembly of the soluble fibers with plurality of molecular weights to create a time controlled dissolution of the functional high and low molecular weight fibers for improving solubility and palatability with improved dietary performance in the oral and gastro-intestinal system is also disclosed herein.

The present invention relates to genetically modified plants by key genes involved in the biosynthesis of steroidal alkaloids. These plants have altered content of steroidal (glyco)alkaloids. Solanaceous crop plants with reduced content of antinutritional steroidal glycoalkaloids are provided.

The present invention relates to farm chemical with glucoside alkaloid as the effective component for preventing and controlling plant mycosis and its application. The fungicidal glucoside alkaloid preparation has up to five kinds of glucoside alkaloid with obvious effect of preventing and controlling plant diseases caused by Verticillium, monospermous rust fungi, Fusarium and other fungi. The fungicidal glucoside alkaloid preparation has broad spectrum, low toxicity, environment friendship, low cost and other features.

The present invention relates to the use of glycoalkaloids, such as solasonine and solamargine, in treatment of cancer such as skin cancer, and to compositions for use in such treatment. More particularly the present invention relates to providing an improved, substantially stable formulation for the glycoalkaloids which minimises or reduces degradation of these active molecules.

A composition comprising at least two glycoalkaloids of formula I: wherein: either one or both of the dotted lines represents a double bond, and the other a single bond, or both represent single bonds; A: represents a radical selected from the following radicals of general formulae (II) to (V): each of R1 is a radical separately selected from the group consisting of hydrogen, amino, oxo and OR4; each of R2 is a radical separately selected from the group consisting of hydrogen, amino and OR4; each of R3 is a radical separately selected from the group consisting of hydrogen, carbohydrate and a carbohydrate derivative; “X” is a radical selected from the group comprising —CH2—, —O— and —NH2—; and wherein the compound includes at least one R4 group that is a carbohydrate or a derivative thereof selected from the group comprising glyceric aldehyde, glycerose, erythrose, threose, ribose, arabinose, xylose, lyxose, altrose, allose, gulose, mannose, glucose, idose, galactose, talose, rhamnose, dihydroxyactone, erythrulose, ribulose, xylulose, psicose, fructose, sorbose, tagatose, and other hexoses, heptoses, octoses, nanoses, decoses, deoxysugars with branched chains, (e.g. apiose, hamamelose, streptose, cordycepose, mycarose and cladinose), compounds wherein the aldehyde, ketone or hydroxyl groups have been substituted (e.g. N-acetyl, acetyl, methyl, replacement of CH2OH), sugar alcohols, sugar acids, benzimidazoles, the enol salts of the carbohydrates, saccharinic acids, sugar phosphates; wherein the ratio of said glycoalkaloids is between 6:1 and 1:6 and on the proviso that when the glycoalkaloids are solamargine and solasonine and they are present in a 1:1 ratio the solamargine and solasonine are isolated.

The invention provides a spirosolane glycoalkaloid(3beta,5alpha,22alpha,25R)-spirosolane-3-O-beta-D-glucopyranosyl-(1 to 2)-O-beta-D-glucopyranosyl-(1 to 4)-beta-D-galactopyranoside, and a preparation method and a use thereof. The spirosolane glycoalkaloid has an inhibition effect on human lung gland cancer cell A549, human maxicell lung cancer cell H460 and human lung squamous cancer cell SK-MES-1, the 50% inhibiting concentration of the A549 cell is 19.22 [mu]g / ml, the 50% inhibiting concentration of the H460 cell is 80.03 [mu]g / ml, and the 50% inhibiting concentration of the SK-MES-1 cell is 54.20 [mu]g / ml. The (3beta,5alpha,22alpha,25R)-spirosolane-3-O-beta-D-glucopyranosyl-(1 to 2)-O-beta-D-glucopyranosyl-(1 to 4)-beta-D-galactopyranoside prepared in the invention, and a preparation thereof, can be used for treating non-small cell lung cancers.

Provided is DNA of biosynthetic enzyme of glycoalkaloid of solanaceous plant (Solanaceae) such as potato. Provided are a protein having activity on a biosynthetic enzyme of glycoalkaloid of solanaceous plant such as potato, and a method of creating and assaying a novel organism using a gene encoding the protein.

The present invention relates to key genes in the biosynthesis of steroidal alkaloids and saponins, including regulatory genes and enzyme-encoding genes, and to use thereof for altering the content of steroidal (glyco)alkaloids or phytosterols in plants. The present invention provides genetically modified plants or gene edited plants with altered content of steroidal (glyco)alkaloids, particularly to Solanaceous crop plants with reduced content of antinutritional steroidal glycoalkaloids and to the increase in phytosterols, including cholesterol or cholestanol in these plants. The present invention also provides methods of altering gene expression.

Provided is DNA of biosynthetic enzyme of glycoalkaloid of solanaceous plant (Solanaceae) such as potato. Provided are a protein having activity on a biosynthetic enzyme of glycoalkaloid of solanaceous plant such as potato, and a method of creating and assaying a novel organism using a gene encoding the protein.

A method for the preparation of a food grade coagulated potato protein concentrate is disclosed. The method comprises the steps of a) separating fibers and starch from a potato pulp, wherein a potatofruit juice containing potato protein is obtained, b) coagulating the potato protein in the potato fruit juice by adjusting the pH to an acidic value and by heating, wherein a coagulated potato protein slurry containing particles of coagulated potato protein is obtained, c) reducing the total glycoalkaloid content in the coagulated potato protein slurry to less than 150 mg / kg protein concentrate,and d) actively reducing the particle size of the of potato protein particles by physical means in the way that a coagulated potato protein concentrate is obtained in which 90 % of the particles havea particle size of less than 55 [mu]m. A food grade coagulated potato protein concentrate produced with the method, use of the food grade coagulated potato protein concentrate in a food product, and afood product for human use comprising the food grade coagulated potato protein product are also disclosed.

The invention relates to a cultivation method for reducing the glycoalkaloid content of potato tubers. The method comprises the steps of pretreatment, sowing, covering soil and ridging, covering blackfilms on ridges, covering soil on the films and the like. The glycoalkaloid content of potato tubers is reduced by adopting a cultivation technology. The cultivation method for reducing the glycoalkaloid content of potato tubers provided by the invention has the advantages of avoiding the emergence of green-head potatoes during the planting process, and improving the appearance quality and ediblesafety of the potato tubers.

The invention discloses a healthcare food with an immunity improving function and a preparation method thereof. The healthcare food is prepared form, by weight, 25-35 parts of millet, 10-20 parts of peach kernels, 10-15 parts of sichuan lovage rhizome, 10-15 parts of verveine, 10-15 parts of spina gleditsiae, 5-10 parts of pumpkin, 5-10 parts of Euphorbia milii, 5-8 parts of Chinese alpine rush, 2-4 parts of clematis chinensis, 2-4 parts of kalmegh extracts, 2-4 parts of natto extracts and 2-4 parts of glycoalkaloids extracts. Compared with the prior art, the obtained healthcare food has no toxic or side effects, has nutritional value and can have the immunity improving function, and it is found through experimental verification that the healthcare food has a remarkable effect of improving immunity.

A composition of chemically purified soluble mannans from legumes' seeds (e.g. Ceratonia siliqua, Cæsalpinia spinosa Trigonelle foenum-graecum, and Cyamopsis tetragonolobus) and their use in the assembly of palatable dietary supplements is disclosed herein. The fractionation process provides high-quality physiologically soluble, chemically modified and purified homogeneous size polysaccharide fibers, devoid of natural impurities, for example proteins, alkaloids, glycoalkaloids, and / or environmental impurities including heavy metals, agricultural residues and microbial toxins. This process provides hypoallergenic dietary fibers devoid of any potential allergens, cytotoxins, and gastrointestinal toxins. A sequential process for assembly of the soluble fibers with plurality of molecular weights to create a time controlled dissolution of the functional high and low molecular weight fibers for improving solubility and palatability with improved dietary performance in the oral and gastro-intestinal system is also disclosed herein.

The invention discloses a special feed additive for Charollais cattle and capable of preventing bovine ruminal tympany, and a preparation method of the feed additive. The special feed additive is a traditional Chinese medicine composition which is prepared from the following components in parts by weight: 8-14 parts of lindera aggregate, 12-16 parts of tangerine peels, 5-8 parts of rhizoma cyperi, 3-5 parts of red tangerine peel, 6-10 parts of ferula, 15-20 parts of sparganium stoloniferum, 10-14 parts of artemisia anomala, 3-5 parts of peach kernels, 5-12 parts of radix aristolochia, 8-16 parts of fructus cannabis, 10-18 parts of folium sennae, 3-8 parts of tetracera asiatica, 9-11 parts of glycoalkaloids, and 3-6 parts of radix ampelopsis. The special feed additive has the beneficial effects that the special feed additive can effectively prevent the bovine ruminal tympany, and is fast to take effect due to preparation of purely traditional Chinese medicines, the toxicity of the additive is reduced, the palatability is far better than that of the existing products, tests proved that the cure rate can achieve more than or equal to 98%, and the market prospects are good.

The invention provides a spirosolane glycoalkaloid(3beta,5alpha,22alpha,25R)-spirosolane-3-O-beta-D-glucopyranosyl-(1 to 2)-O-beta-D-glucopyranosyl-(1 to 4)-beta-D-galactopyranoside, and a preparation method and a use thereof. The spirosolane glycoalkaloid has an inhibition effect on human lung gland cancer cell A549, human maxicell lung cancer cell H460 and human lung squamous cancer cell SK-MES-1, the 50% inhibiting concentration of the A549 cell is 19.22 [mu]g / ml, the 50% inhibiting concentration of the H460 cell is 80.03 [mu]g / ml, and the 50% inhibiting concentration of the SK-MES-1 cell is 54.20 [mu]g / ml. The (3beta,5alpha,22alpha,25R)-spirosolane-3-O-beta-D-glucopyranosyl-(1 to 2)-O-beta-D-glucopyranosyl-(1 to 4)-beta-D-galactopyranoside prepared in the invention, and a preparation thereof, can be used for treating non-small cell lung cancers.

The invention discloses a traditional Chinese medicine composition for treating esophageal cancer and a preparation method of the traditional Chinese medicine composition, and belongs to the technicalfield of traditional Chinese medicine preparation. The traditional Chinese medicine composition for treating the esophageal cancer is prepared from the following medicinal materials in parts by weight: 50 parts of glycoalkaloids, 50 parts of solanum lyratum thumb, 28 parts of indian mockstrawberry herb, 25 parts of chinese sage herb, 30 parts of bidens bipinnata, 30 parts of scutellariae barbatae, 15 parts of rotten folium citri reticulatae, 15 parts of clematis chinensis, 20 parts ofpleione bulbocodioides, 40 parts of human placenta, 20 parts of flos lonicerae, 5 parts of centipede, 20 partsof scorpion, 20 parts of earthworm, 40 parts of ginseng, 20 parts of ganoderma lucidum, 40 parts of american ginseng, 40 parts of sarcandra glabra, 40 parts of water pseudo-ginseng, 20 parts of resina draconis, 40 parts of bletilla striata, and 20 parts of radix glycyrrhizae. The traditional Chinese medicine composition for treating the esophageal cancer adopts drug matching, the effects that thegrowth of cancer cells is prevented, the metastasis and recurrence of the cancer cells are prevented, and the cancer cells are killed and fixed so as to achieve the goal of curing the esophageal cancer are achieved.

Provided are the DNA of a glycoalkaloid biosynthetic enzyme of solanaceous plants (Solanaceae) such as potato, solanaceous plants producing no glycoalkaloids, and a method of producing a cultivar with a reduced risk of accumulating glycoalkaloids, which involves crossing plants in which the expression of an oxidase gene involved in glycoalkaloid biosynthesis is suppressed or the activity of the enzyme is lowered, as mother plants, and screening progeny resulting from the crossing.

The present invention relates to genetically modified plants by key genes involved in the biosynthesis of steroidal alkaloids. These plants have altered content of steroidal (glyco)alkaloids. Solanaceous crop plants with reduced content of antinutritional steroidal glycoalkaloids are provided.

The present invention relates to the use of glycoalkaloids, such as solasonine and solamargine, in treatment of cancer such as skin cancer, and to compositions for use in such treatment. More particularly the present invention relates to providing an improved, substantially stable formulation for the glycoalkaloids which minimises or reduces degradation of these active molecules.

The invention belongs to the field of pharmaceutical combination, in particular to a pharmaceutical composition for treating cancerous pain in anesthesia department and a preparation method of the pharmaceutical composition. In view of the problem that existing drugs cannot suppress pain from various aspects such as oral administration, external use and body conditioning, the following solution isproposed. The solution comprises the steps that oral administration agentia and external use ointment are included, the oral administration agentia is prepared from ganoderma lucidum, ginseng, caterpillar fungus, flos campsis, red peony root, manyprickle acanthopanax root, radix curcuma, radix codonopsis, matrine, citrus, amomum, polyporus umbellatus and glycoalkaloids, and the external use ointment is prepared from rubia cordifolia, indigo naturalis, cornus officinalis, gallnut, pinellia ternate, honey, plant oil and scutellariae barbatae. The oral administration agentia and the external useointment are used for treating the cancerous position of a patient at the same time, the simultaneous use of oral administration and external use can significantly relieve the pain of the cancerous position of the cancer patient, the metastatic spread of cancer cells is reduced, and meanwhile, the effects of enhancing the physiological function of the patient and improving patient immunity are achieved.